Strengthening evidence for active surveillance for prostate cancerKLOTZ, Laurence.European urology. 2013, Vol 63, Num 1, pp 108-110, issn 0302-2838, 3 p.Article

Active surveillance for favorable risk prostate cancer : Rationale, risks, and resultsKLOTZ, Laurence.Urologic oncology. 2007, Vol 25, Num 6, pp 505-509, issn 1078-1439, 5 p.Conference Paper

Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancerKLOTZ, Laurence.European urology. 2005, Vol 47, Num 1, pp 16-21, issn 0302-2838, 6 p.Article

Active surveillance for prostate cancer : For whom?KLOTZ, Laurence.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8165-8169, issn 0732-183X, 5 p.Article

Active surveillance for prostate cancer : trials and tribulationsKLOTZ, Laurence.World journal of urology (Print). 2008, Vol 26, Num 5, pp 437-442, issn 0724-4983, 6 p.Article

Role of saturation biopsy in the detection of prostate cancer among difficult diagnostic casesFLESHNER, Neil; KLOTZ, Laurence.Urology (Ridgewood, NJ). 2002, Vol 60, Num 1, pp 93-97, issn 0090-4295Article

Results of unilateral genitofemoral nerve grafts with contralateral nerve sparing during radical prostatectomyJOFFE, Rob; KLOTZ, Laurence H.Urology (Ridgewood, NJ). 2007, Vol 69, Num 6, pp 1161-1164, issn 0090-4295, 4 p.Article

Active Surveillance for Prostate Cancer: Progress and PromiseCOOPERBERG, Matthew R; CARROLL, Peter R; KLOTZ, Laurence et al.Journal of clinical oncology. 2011, Vol 29, Num 27, pp 3669-3676, issn 0732-183X, 8 p.Article

Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell linesVENKATESWARAN, Vasundara; FLESHNER, Neil E; KLOTZ, Laurence H et al.The Journal of urology. 2002, Vol 168, Num 4, pp 1578-1582, issn 0022-5347, 1Article

Prostate Cancer Death of Men Treated With Initial Active Surveillance: Clinical and Biochemical CharacteristicsKRAKOWSKY, Yonah; LOBLAW, Andrew; KLOTZ, Laurence et al.The Journal of urology. 2010, Vol 184, Num 1, pp 131-135, issn 0022-5347, 5 p.Article

Cardiovascular effects of androgen depletion and replacement therapyPINTHUS, Jehonathan H; TRACHTENBERG, John; KLOTZ, Laurence et al.Urology (Ridgewood, NJ). 2006, Vol 67, Num 6, pp 1126-1132, issn 0090-4295, 7 p.Article

Active Surveillance: The Canadian Experience With an Inclusive ApproachKLOTZ, Laurence.Journal of the National Cancer Institute. Monographs. 2012, Vol 45, pp 234-241, issn 1052-6773, 8 p.Conference Paper

Locally advanced prostate cancer- : Biochemical results from a prospective phase ii study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapyBRUCHOVSKY, Nicholas; KLOTZ, Laurence; CROOK, Juanita et al.Cancer. 2007, Vol 109, Num 5, pp 858-867, issn 0008-543X, 10 p.Article

Modeling prostate specific antigen kinetics in patients on active surveillanceLIYING ZHANG; LOBLAW, Andrew; KLOTZ, Laurence et al.The Journal of urology. 2006, Vol 176, Num 4, pp 1392-1398, issn 0022-5347, 7 p., 1Article

Critical evaluation of hormonal therapy for carcinoma of the prostateCHODAK, Gerald W; KEANE, Thomas; KLOTZ, Laurence et al.Urology (Ridgewood, NJ). 2002, Vol 60, Num 2, pp 201-208, issn 0090-4295Article

Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to DegarelixCRAWFORD, E. David; SHORE, Neal D; KLOTZ, Laurence et al.Urology (Ridgewood, NJ). 2014, Vol 83, Num 5, pp 1122-1128, issn 0090-4295, 7 p.Article

A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaVAN POPPEL, Hendrik; DA POZZO, Luigi; CLAESSENS, Ilse et al.European urology. 2007, Vol 51, Num 6, pp 1606-1615, issn 0302-2838, 10 p.Article

Variation in patterns of practice in diagnosing screen-detected prostate cancerNAM, Robert K; TOI, Ants; TRACHTENBERG, John et al.BJU international (Papier). 2004, Vol 94, Num 9, pp 1239-1244, issn 1464-4096, 6 p.Article

p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. Commentary. Authors' replyFLESHNER, Neil; KAPUSTA, Linda; EZER, Darren et al.The Journal of urology. 2000, Vol 164, Num 4, pp 1177-1182, issn 0022-5347Article

Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyCROOK, Juanita M; O'CALLAGHAN, Christopher J; WARDE, Padraig et al.The New England journal of medicine. 2012, Vol 367, Num 10, pp 895-903, issn 0028-4793, 9 p.Article

The efficacy and safety of degarelix : a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerKLOTZ, Laurence; BOCCON-GIBOD, Laurent; SHORE, Neal D et al.BJU international (Papier). 2008, Vol 102, Num 11, pp 1531-1538, issn 1464-4096, 8 p.Article

Outcomes of treatment vs observation of localized prostate cancer in elderly men. Authors' replyALBERTSEN, Peter C; LU-YAO, Grace L; SCHWARTZ, J. Sanford et al.JAMA, the journal of the American Medical Association. 2007, Vol 297, Num 15, pp 1651-1653, issn 0098-7484, 3 p.Article

Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. DiscussionKLOTZ, Laurence; SELLERS, William R; SMITH, Matthew R et al.The Journal of urology. 2004, Vol 172, Num 5, pp S48-S51, issn 0022-5347, 2Conference Paper

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. DiscussionSMITH, Matthew R; KLOTZ, Laurence; CARROLL, Peter R et al.The Journal of urology. 2004, Vol 172, Num 5, pp S52-S57, issn 0022-5347, 2Conference Paper

The role of inflammation in the pathogenesis of prostate cancer. DiscussionNELSON, William G; DE MARZO, Angelo M; DEWEESE, Theodore L et al.The Journal of urology. 2004, Vol 172, Num 5, pp S6-S12, issn 0022-5347, 2Conference Paper